Augmented tonic pain-related behavior in knockout mice lacking monoacylglycerol lipase, a major degrading enzyme for the endocannabinoid 2-arachidonoylglycerol

Behavioural Brain Research

Volumn 271, Issue , 2014, Pages 51-58

  Petrenko, Andrey B ^a   Yamazaki, Maya ^b   Sakimura, Kenji ^b   Kano, Masanobu ^c   Baba, Hiroshi ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b NIIGATA UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

Acetic acid test; Formalin test; Monoacylglycerol lipase knockout mice; Proalgesic effect; Tonic pain

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ACYLGLYCEROL LIPASE; 1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 1,3 BENZODIOXOLE DERIVATIVE; 2-ARACHIDONYLGLYCEROL; 4 [BIS(1,3 BENZODIOXOL 5 YL)HYDROXYMETHYL] 1 PIPERIDINECARBOXYLIC ACID 4 NITROPHENYL ESTER; ACYLGLYCEROL; ACYLGLYCEROL KINASE; ARACHIDONIC ACID DERIVATIVE; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AFFECTING AGENT; ENDOCANNABINOID; PHOSPHOTRANSFERASE; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ADULT; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC PAIN; CONTROLLED STUDY; ENZYME ACTIVITY; INFLAMMATORY PAIN; KNOCKOUT MOUSE; MALE; MOUSE; NEUROPATHIC PAIN; NOCICEPTIVE STIMULATION; NONHUMAN; PAIN; PAIN ASSESSMENT; PAIN THRESHOLD; PRIORITY JOURNAL; VISCERAL PAIN; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CBA MOUSE; CHEMICALLY INDUCED; DEFICIENCY; DRUG EFFECTS; INFLAMMATION; METABOLISM; NEURALGIA; PATHOPHYSIOLOGY;

ANIMALS; ARACHIDONIC ACIDS; BENZODIOXOLES; CANNABINOID RECEPTOR MODULATORS; ENDOCANNABINOIDS; GLYCERIDES; INFLAMMATION; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED CBA; MICE, KNOCKOUT; NEURALGIA; PAIN; PAIN THRESHOLD; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1;

EID: 84902515498     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2014.05.063     Document Type: Article

References (43)

1. Atwood B.K., Mackie K. CB2: a cannabinoid receptor with an identity crisis. Br J Pharmacol 2010, 160:467-479.
2. Pertwee R.G. The pharmacology of cannabinoid receptors and their ligands: an overview. Int J Obes (Lond) 2006, 30(Suppl. 1):S13-S18.
3. Kano M., Ohno-Shosaku T., Hashimotodani Y., Uchigashima M., Watanabe M. Endocannabinoid-mediated control of synaptic transmission. Physiol Rev 2009, 89:309-380.
4. Luchicchi A., Pistis M. Anandamide and 2-arachidonoylglycerol: pharmacological properties, functional features, and emerging specificities of the two major endocannabinoids. Mol Neurobiol 2012, 46:374-392.
5. Ohno-Shosaku T., Tanimura A., Hashimotodani Y., Kano M. Endocannabinoids and retrograde modulation of synaptic transmission. Neuroscientist 2012, 18:119-132.
6. Calignano A., La Rana G., Giuffrida A., Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature 1998, 394:277-281.
7. Alvarez-Jaimes L.J., Palmer J.A. The role of endocannabinoids in pain modulation and the therapeutic potential of inhibiting their enzymatic degradation. Curr Pharm Biotechnol 2011, 12:1644-1659.
8. Ahn K., Johnson D.S., Cravatt B.F. Fatty acid amide hydrolase as a potential therapeutic target for the treatment of pain and CNS disorders. Expert Opin Drug Discov 2009, 4:763-784.
9. Fowler C.J. Monoacylglycerol lipase - a target for drug development. Br J Pharmacol 2012, 166:1568-1585.
10. Desroches J., Guindon J., Lambert C., Beaulieu P. Modulation of the anti-nociceptive effects of 2-arachidonoyl glycerol by peripherally administered FAAH and MGL inhibitors in a neuropathic pain model. Br J Pharmacol 2008, 155:913-924.
11. Guindon J., Guijarro A., Piomelli D., Hohmann A.G. Peripheral antinociceptive effects of inhibitors of monoacylglycerol lipase in a rat model of inflammatory pain. Br J Pharmacol 2011, 163:1464-1478.
12. Kinsey S.G., Long J.Z., O'neal S.T., Abdullah R.A., Poklis J.L., Boger D.L., et al. Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain. J Pharmacol Exp Ther 2009, 330:902-910.
13. Long J.Z., Li W., Booker L., Burston J.J., Kinsey S.G., Schlosburg J.E., et al. Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol 2009, 5:37-44.
14. Chanda P.K., Gao Y., Mark L., Btesh J., Strassle B.W., Lu P., et al. Monoacylglycerol lipase activity is a critical modulator of the tone and integrity of the endocannabinoid system. Mol Pharmacol 2010, 78:996-1003.
15. Schlosburg J.E., Blankman J.L., Long J.Z., Nomura D.K., Pan B., Kinsey S.G., et al. Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. Nat Neurosci 2010, 13:1113-1119.
16. Mogil J.S., Grisel J.E. Transgenic studies of pain. Pain 1998, 77:107-128.
17. Mulvihill M.M., Nomura D.K. Therapeutic potential of monoacylglycerol lipase inhibitors. Life Sci 2013, 92:492-497.
18. Huggins J.P., Smart T.S., Langman S., Taylor L., Young T. An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee. Pain 2012, 153:1837-1846.
19. Nakamura K., Manabe T., Watanabe M., Mamiya T., Ichikawa R., Kiyama Y., et al. Enhancement of hippocampal LTP, reference memory and sensorimotor gating in mutant mice lacking a telencephalon-specific cell adhesion molecule. Eur J Neurosci 2001, 13:179-189.
20. Tanimura A., Uchigashima M., Yamazaki M., Uesaka N., Mikuni T., Abe M., et al. Synapse type-independent degradation of the endocannabinoid 2-arachidonoylglycerol after retrograde synaptic suppression. Proc Natl Acad Sci U S A 2012, 109:12195-12200.
21. Uchigashima M., Yamazaki M., Yamasaki M., Tanimura A., Sakimura K., Kano M., et al. Molecular and morphological configuration for 2-arachidonoylglycerol-mediated retrograde signaling at mossy cell-granule cell synapses in the dentate gyrus. J Neurosci 2011, 31:7700-7714.
22. Woolfe G., Macdonald A.D. The evaluation of the analgesic action of pethidine hydrochloride (demerol). J Pharmacol Exp Ther 1944, 80:300-307.
23. Haffner F. Experimentelle Prüfung schmerzstillender Mittel. Dtsch Med Wochenschr 1929, 55:731-733.
24. Hunskaar S., Fasmer O.B., Hole K. Formalin test in mice, a useful technique for evaluating mild analgesics. J Neurosci Methods 1985, 14:69-76.
25. Koster R., Anderson M., De Beer E. Acetic acid for analgesic screening. Fed Proc 1959, 18:412.
26. Iadarola M.J., Brady L.S., Draisci G., Dubner R. Enhancement of dynorphin gene expression in spinal cord following experimental inflammation: stimulus specificity, behavioral parameters and opioid receptor binding. Pain 1988, 35:313-326.
27. Petrenko A.B., Yamakura T., Askalany A.R., Kohno T., Sakimura K., Baba H. Effects of ketamine on acute somatic nociception in wild-type and N-methyl-D-aspartate (NMDA) receptor epsilon1 subunit knockout mice. Neuropharmacology 2006, 50:741-747.
28. Ishii H., Petrenko A.B., Kohno T., Baba H. No evidence for the development of acute analgesic tolerance during and hyperalgesia after prolonged remifentanil administration in mice. Mol Pain 2013, 9:11.
29. Decosterd I., Woolf C.J. Spared nerve injury: an animal model of persistent peripheral neuropathic pain. Pain 2000, 87:149-158.
30. Tal M., Bennett G.J. Extra-territorial pain in rats with a peripheral mononeuropathy: mechano-hyperalgesia and mechano-allodynia in the territory of an uninjured nerve. Pain 1994, 57:375-382.
31. Petrenko A.B., Tsujita M., Kohno T., Sakimura K., Baba H. Mutation of alpha1G T-type calcium channels in mice does not change anesthetic requirements for loss of the righting reflex and minimum alveolar concentration but delays the onset of anesthetic induction. Anesthesiology 2007, 106:1177-1185.
32. Taschler U., Radner F.P., Heier C., Schreiber R., Schweiger M., Schoiswohl G., et al. Monoglyceride lipase deficiency in mice impairs lipolysis and attenuates diet-induced insulin resistance. J Biol Chem 2011, 286:17467-17477.
33. Agarwal N., Pacher P., Tegeder I., Amaya F., Constantin C.E., Brenner G.J., et al. Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci 2007, 10:870-879.
34. Clapper J.R., Moreno-Sanz G., Russo R., Guijarro A., Vacondio F., Duranti A., et al. Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism. Nat Neurosci 2010, 13:1265-1270.
35. Ren K., Dubner R. Inflammatory models of pain and hyperalgesia. ILAR J 1999, 40:111-118.
36. Abbadie C., Taylor B.K., Peterson M.A., Basbaum A.I. Differential contribution of the two phases of the formalin test to the pattern of c-fos expression in the rat spinal cord: studies with remifentanil and lidocaine. Pain 1997, 69:101-110.
37. Taylor B.K., Peterson M.A., Basbaum A.I. Persistent cardiovascular and behavioral nociceptive responses to subcutaneous formalin require peripheral nerve input. J Neurosci 1995, 15:7575-7584.
38. Latremoliere A., Woolf C.J. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain 2009, 10:895-926.
39. Vincenzi F., Targa M., Corciulo C., Tabrizi M.A., Merighi S., Gessi S., et al. Antinociceptive effects of the selective CB2 agonist MT178 in inflammatory and chronic rodent pain models. Pain 2013, 154:864-873.
40. Jhaveri M.D., Sagar D.R., Elmes S.J., Kendall D.A., Chapman V. Cannabinoid CB2 receptor-mediated anti-nociception in models of acute and chronic pain. Mol Neurobiol 2007, 36:26-35.
41. Ghosh S., Wise L.E., Chen Y., Gujjar R., Mahadevan A., Cravatt B.F., et al. The monoacylglycerol lipase inhibitor JZL184 suppresses inflammatory pain in the mouse carrageenan model. Life Sci 2013, 92:498-505.
42. Nomura D.K., Morrison B.E., Blankman J.L., Long J.Z., Kinsey S.G., Marcondes M.C., et al. Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science 2011, 334:809-813.
43. Valdeolivas S., Pazos M.R., Bisogno T., Piscitelli F., Iannotti F.A., Allara M., et al. The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, rather than enhancing striatal damage, protects striatal neurons from malonate-induced death: a potential role of cyclooxygenase-2-dependent metabolism of 2-AG. Cell Death Dis 2013, 4:e862.